Total medical devices industry M&A deals in Q2 2020 worth $1.78bn were announced in the US, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 7.9% over the previous quarter and a drop of 71.3% when compared with the last four-quarter average of $6.19bn.
The US held a 79.05% share of the global medical devices industry M&A deal value that totalled $2.25bn in Q2 2020.
In terms of deal activity, the US recorded 48 deals during Q2 2020, marking a drop of 15.8% over the previous quarter and a drop of 11.1% over the last four-quarter average.
The US medical devices industry M&A deals in Q2 2020: Top deals
The top five medical devices industry M&A deals accounted for 98.6% of the overall value during Q2 2020.
The combined value of the top five medical devices M&A deals stood at $1.75bn, against the overall value of $1.78bn recorded for the month.
The top five medical devices industry deals of Q2 2020 tracked by GlobalData were:
2) The $200m asset transaction with CareZone by Walmart
3) LeMaitre Vascular’s $90m acquisition of Artegraft
5) My Next Health’s asset transaction with for $30m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.